The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Toxicity and outcomes of BRAF and MEK inhibitor “ramp-up” dosing strategies for patients with melanoma: A real-world institutional experience.
 
Benjamin Switzer
No Relationships to Disclose
 
Sabah Alaklabi
No Relationships to Disclose
 
Arya Mariam Roy
No Relationships to Disclose
 
Kristopher Attwood
No Relationships to Disclose
 
Chong Wang
No Relationships to Disclose
 
Lamya Hamad
Consulting or Advisory Role - Bristol Myers Squibb Foundation
 
Tammy Sessanna
No Relationships to Disclose
 
Michele Nanni
No Relationships to Disclose
 
Yeliam Patel
No Relationships to Disclose
 
Igor Puzanov
Stock and Other Ownership Interests - Celldex; Celldex (I)
Consulting or Advisory Role - Amgen; Iovance Biotherapeutics; Merck; Nektar; Nouscom; Oncorus; Roche; Seneca Therapeutics